SCHEMBL2174566

SCHEMBL2174566

O[C@@H](CCI)c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
KMT2A Q03164 1/20 0.51
HTR1A P08908 2/20 0.44
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
KEAP1 Q14145 1/20 0.42
SLC5A2 P31639 1/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALOX5 P09917 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2964417 1.00 NPC1 (0.51) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL4440609 0.87 NPC1 (0.57) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL3229012 0.82 NPC1 (0.53) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL14525329 0.82 NPC1 (0.53) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL14386089 0.80 NPC1 (0.51) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL1232311 0.80 NPC1 (0.55) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL1264082 0.80 NPC1 (0.55) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL5684870 0.80 NPC1 (0.51) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL1200723 0.80 NPC1 (0.55) NPC1RAB9AKMT2AHTR1ACES2
SCHEMBL5834937 0.80 NPC1 (0.51) NPC1RAB9AKMT2AHTR1ACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501967-B2 Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols LONZA AG (CH) 2013-08-06 US disclosed
US-20120316350-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS LONZA AG (CH) 2012-12-13 US disclosed
US-8258338-B2 Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols LONZA AG (CH) 2012-09-04 US disclosed
EP-1720852-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS LONZA AG (CH) 2012-07-11 EP disclosed
US-8193380-B2 Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols LONZA AG (CH) 2012-06-05 US disclosed
CN-102392059-A Synthetic method of (S)-(-)-N,N-dimethyl-3-hydroxy-3-(2-thiophene)propylamine LIANYUNGANG HONGYE CHEMICAL CO LTD 2012-03-28 CN disclosed
US-20110207946-A1 Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols LONZA AG (CH) 2011-08-25 US disclosed
US-7973182-B2 enantiomerically pure 1-substituted-3-amino-alcohols, particularly of (S)-(-)- and (R)-(+)-3-N-methylamino-1-(2-thienyl)-1-propanol, by asymmetrically hydrogenating salts of a carboxylic acids with an aminoketone of the formula: LONZA LTD. (CH) 2011-07-05 US disclosed
US-20090156833-A1 Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols LONZA AG (CH) 2009-06-18 US disclosed
US-20080154047-A1 Process For the Preparation of Enantiomerically Pure1-Substitued-3-Aminoalcohols LONZA AG (CH) 2008-06-26 US disclosed
EP-1566383-A1 Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols Lonza AG (CH) 2005-08-24 EP disclosed
WO-2004031168-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OPTICALLY ACTIVE 3-AMINO-1-(2-THIENYL)-1-PROPANOL DERIVATIVES LONZA AG (CH) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207946-A1 Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols ALDH7A1, BCKDK, AASDHPPT NPC1 4004/4885RAB9A 3731/4885KMT2A 875/4885
US-20120316350-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS CYP2S1, AKR1C3, AKR1B10 NPC1 3835/4885RAB9A 2680/4885KMT2A 525/4885
US-20090156833-A1 Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols CYP2S1, AKR1C3, ADSL NPC1 3958/4885RAB9A 2362/4885KMT2A 1200/4885
US-20080154047-A1 Process For the Preparation of Enantiomerically Pure1-Substitued-3-Aminoalcohols ADH1A, ADH1C, ALDH7A1 NPC1 3230/4885RAB9A 3538/4885KMT2A 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.